undefined | Better HN

0 pointstzs5y ago0 comments

The comment by Barleyman on the Ars Technica article on this [1] has a graphic from someplace called the Winston Centre for Risk Analysis that shows the benefits in COVID reduction vs the harms from the AZ vaccine by age group.

According to that graphic, if you are in a time of medium COVID infection rates (60 per 100k per day), the risk from COVID outweighs the vaccine risks in that age group. If you in a time of low rates (20 per 100k per day) the vaccine risks outweigh the COVID risks.

The vaccine risk goes down as patient age goes up, and the COVID risk goes up as age goes up.

The J&J risks will probably follow a similar pattern and it also appears that the J&J clots require unusual treatment. That suggests a pause to at least figure out where the risk curves cross and to make sure that doctors and hospitals are prepared to recognize and treat the J&J clots.

[1] https://arstechnica.com/science/2021/04/us-cdc-fda-call-for-...

0 comments

1 comments · 1 top-level

bitcurious5y ago

That’s excellent, thank you for sharing! The comment you linked to suggests that the gender disparity can be attributed to women being over-represented in getting the vaccine, but I’m not sure the logic holds. Medical professionals were mostly done being vaccinated prior to J&J being approved.

j / k navigate · click thread line to collapse